Tiziana Life Sciences Ltd. (TLSA) announced the submission of its Investigational New Drug or IND application to the FDA for a Phase 2 clinical trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, aimed at treating Amyotrophic Lateral Sclerosis or ALS.
The submission follows the receipt of a grant from the ALS Association, supporting the company's commitment to advancing new treatment approaches for ALS.
Tiziana plans to initiate a 20-patient trial evaluating the safety and early-stage efficacy of intranasal foralumab upon FDA clearance of the IND application.
The trial will assess the safety profile and disease improvement in ALS patients, with the primary goal to evaluate early-stage parameters of disease progression.
Intranasal foralumab is expected to offer a novel immunomodulatory approach to treat ALS, a disease with limited treatment options and a rapid progression.
Tiziana's lead candidate, intranasal foralumab, is currently being studied in other neurodegenerative diseases, including Multiple Sclerosis and Alzheimer's disease.
The company aims to provide innovative solutions for ALS patients, addressing an urgent unmet need in the field of neurodegenerative treatments.
Currently, TLSA is trading at $1.11 down by 1.69 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.